In vitro electrophysiological drug testing using human embryonic stem cell derived cardiomyocytes

Stem Cells and Development

Volumn 18, Issue 1, 2009, Pages 161-172

  Caspi, Oren ^a   Itzhaki, Ilanit ^a   Kehat, Izhak ^a,b   Gepstein, Amira ^a   Arbel, Gil ^a   Huber, Irit ^a   Satin, Jonathan ^c   Gepstein, Lior ^a,b  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b RAMBAM MEDICAL CENTER   (Israel)

^c UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [2 (6 METHYL 2 PYRIDYL)ETHYL] 4 (4 METHYLSULFONYLAMINOBENZOYL)PIPERIDINE; CISAPRIDE; HEPTANOL; PROCAINAMIDE ETHOBROMIDE; PROPAFENONE; QUINIDINE; SODIUM CHANNEL BLOCKING AGENT; SOTALOL; ANTIARRHYTHMIC AGENT; ENZYME INHIBITOR; ERG1 POTASSIUM CHANNEL; POTASSIUM CHANNEL HERG; PROCAINAMIDE; RNA; SEROTONIN AGONIST;

ARRHYTHMOGENESIS; ARTICLE; CELL MEMBRANE DEPOLARIZATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG SCREENING; ELECTROPHYSIOLOGY; EMBRYO; EMBRYONIC STEM CELL; GAP JUNCTION; HEART MUSCLE; HEART MUSCLE CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; MEMBRANE POTENTIAL; MICROELECTRODE; MUSCLE TISSUE; PRIORITY JOURNAL; QT INTERVAL; REPOLARIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ACTION POTENTIAL; CELL CULTURE; CELL DIFFERENTIATION; CYTOLOGY; DRUG EFFECTS; GENETICS; METABOLISM; PHYSIOLOGY; PROCEDURES;

ACTION POTENTIALS; ANTI-ARRHYTHMIA AGENTS; CELL DIFFERENTIATION; CELLS, CULTURED; CISAPRIDE; DRUG EVALUATION, PRECLINICAL; ELECTROPHYSIOLOGY; EMBRYONIC STEM CELLS; ENZYME INHIBITORS; ETHER-A-GO-GO POTASSIUM CHANNELS; HUMANS; MYOCYTES, CARDIAC; PROCAINAMIDE; QUINIDINE; RNA; SEROTONIN RECEPTOR AGONISTS; SOTALOL;

EID: 60149107033     PISSN: 15473287     EISSN: None     Source Type: Journal    
DOI: 10.1089/scd.2007.0280     Document Type: Article

References (43)

1. Carlsson L. (2006). In vitro and in vivo models for testing arrhythmogenesis in drugs. J Intern Med 259:70-80.
2. Kannankeril PJ and DM Roden. (2007). Drug-induced long QT and torsade de pointes: recent advances. Curr Opin Cardiol 22:39-43.
3. Fermini B and AA Fossa. (2003). The impact of drug-induced QT interval prolongation on drug discovery and development. Nat Rev Drug Discov 2:439-447.
4. Roden DM. (2004). Drug-induced prolongation of the QT interval. N Engl J Med 350:1013-1022.
5. Finlayson K, HJ Witchel, J McCulloch and J Sharkey. (2004). Acquired QT interval prolongation and HERG: implications for drug discovery and development. Eur J Pharmacol 500:129-142.
6. Finlayson K, AJ Pennington and JS Kelly. (2001). [3H]dofetilide binding in SHSY5Y and HEK293 cells expressing a HERG-like K+ channel? Eur J Pharmacol 412:203-212.
7. Dorian P and D Newman. (2000). Rate dependence of the effect of antiarrhythmic drugs delaying cardiac repolarization: an overview. Europace 2:277-285.
8. Thomson JA, J Itskovitz-Eldor, SS Shapiro, MA Waknitz, JJ Swiergiel, VS Marshall and JM Jones. (1998). Embryonic stem cell lines derived from human blastocysts. Science 282:1145-1147.
9. Reubinoff BE, MF Pera, CY Fong, A Trounson and A Bongso. (2000). Embryonic stem cell lines from human blastocysts: somatic differentiation in vitro. Nat Biotechnol 18:399-404.
10. Kehat I, D Kenyagin-Karsenti, M Snir, H Segev, M Amit, A Gepstein, E Livne, O Binah, J Itskovitz-Eldor and L Gepstein. (2001). Human embryonic stem cells can differentiate into myocytes with structural and functional properties of cardiomyocytes. J Clin Invest 108:407-414.
11. Xu C, S Police, N Rao and MK Carpenter. (2002). Characterization and enrichment of cardiomyocytes derived from human embryonic stem cells. Circ Res 91:501-508.
12. Mummery C, D Ward-van Oostwaard, P Doevendans, R Spijker, S van den Brink, R Hassink, M van der Heyden, T Opthof, M Pera, AB de la Riviere, R Passier and L Tertoolen. (2003). Differentiation of human embryonic stem cells to cardiomyocytes: role of coculture with visceral endoderm-like cells. Circulation 107:2733-2740.
13. He JQ, Y Ma, Y Lee, JA Thomson and TJ Kamp. (2003). Human embryonic stem cells develop into multiple types of cardiac myocytes: action potential characterization. Circ Res 93:32-39.
14. Kehat I, A Gepstein, A Spira, J Itskovitz-Eldor and L Gepstein. (2002). High-resolution electrophysiological assessment of human embryonic stem cell-derived cardiomyocytes: a novel in vitro model for the study of conduction. Circ Res 91:659-661.
15. Amit M, MK Carpenter, MS Inokuma, CP Chiu, CP Harris, MA Waknitz, J Itskovitz-Eldor and JA Thomson. (2000). Clonally derived human embryonic stem cell lines maintain pluripotency and proliferative potential for prolonged periods of culture. Dev Biol 227:271-278.
16. Satin J, I Kehat, O Caspi, I Huber, G Arbel, I Itzhaki, J Magyar, EA Schroder, I Perlman and L Gepstein. (2004). Mechanism of spontaneous excitability in human embryonic stem cell derived cardiomyocytes. J Physiol 559:479-496.
17. Meiry G, Y Reisner, Y Feld, S Goldberg, M Rosen, N Ziv and O Binah. (2001). Evolution of action potential propagation and repolarization in cultured neonatal rat ventricular myocytes. J Cardiovasc Electrophysiol 12:1269-1277.
18. Feld Y, M Melamed-Frank, I Kehat, D Tal, S Marom and L Gepstein. (2002). Electrophysiological modulation of cardiomyocytic tissue by transfected fibroblasts expressing potassium channels: a novel strategy to manipulate excitability. Circulation 105:522-529.
19. Igelmund P, BK Fleischmann, IR Fischer, J Soest, O Gryshchenko, MM Bohm-Pinger, H Sauer, Q Liu and J Hescheler. (1999). Action potential propagation failures in long-term recordings from embryonic stem cell-derived cardiomyocytes in tissue culture. Pflugers Arch 437:669-679.
20. Meyer T, C Leisgen, B Gonser and E Gunther. (2004). QT-screen: high-throughput cardiac safety pharmacology by extracellular electrophysiology on primary cardiac myocytes. Assay Drug Dev Technol 2:507-514.
21. Halbach M, U Egert, J Hescheler and K Banach. (2003). Estimation of action potential changes from field potential recordings in multicellular mouse cardiac myocyte cultures. Cell Physiol Biochem 13:271-284.
22. Reppel M, P Igelmund, U Egert, F Juchelka, J Hescheler and I Drobinskaya. (2007). Effect of cardioactive drugs on action potential generation and propagation in embryonic stem cell-derived cardiomyocytes. Cell Physiol Biochem 19:213-224.
23. Ducroq J, R Printemps, S Guilbot, J Gardette, C Salvetat and M Le Grand. (2007). Action potential experiments complete hERG assay and QT-interval measurements in cardiac preclinical studies. J Pharmacol Toxicol Methods 56:159-170.
24. Bauer A, PA Schnabel, KD Schreiner, R Becker, F Voss, P Kraft, J Senges, M Licka, W Kubler and W Schoels. (2001). Effects of propafenone on anisotropic conduction properties within the three-dimensional structure of the canine ventricular wall. Basic Res Cardiol 96:175-183.
25. Sims JJ, KL Schoff, JM Loeb and NA Wiegert. (2003). Regional gap junction inhibition increases defibrillation thresholds. Am J Physiol Heart Circ Physiol 285:H10-16.
26. Roden DM. (2001). Principles in pharmacogenetics. Epilepsia 42 Suppl 5:44-48.
27. Roden DM. (2001). Pharmacogenetics and drug-induced arrhythmias. Cardiovasc Res 50:224-231.
28. International Conference on Harmonisation; guidance on S7B Nonclinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals; availability. (2005). Notice. Fed Regist 70:61133-61134.
29. Food and Drug Administration HHS. International Conference on Harmonisation Guidance on E14 Clinical Evaluation of QT/ QTC Interval Prolongation and Pro-arrhythmic Potential for Non-antiarrhythmic Drugs; availability. (2005). Notice. Fed Regist 70(202):61134-5.
30. European Agency for the Evaluation of Medicinal Products (EMEA). Evaluation of QT/QTC Interval Prolongation and Proarrhythmic Potential for Non-antiarrhythmic Drugs. http://www.emea.europa.eu/pdfs/human/ich/00024en.pdf.
31. Mummery C, D Ward-van Oostwaard, P Doevendans, R Spijker, S van den Brink, R Hassink, M van der Heyden, T Opthof, M Pera, AB de la Riviere, R Passier and L Tertoolen. (2003). Differentiation of human embryonic stem cells to cardiomyocytes: role of coculture with visceral endoderm-like cells. Circulation 107:2733-2740.
32. He JQ, Y Ma, Y Lee, JA Thomson and TJ Kamp. (2003). Human embryonic stem cells develop into multiple types of cardiac myocytes. Action potential characterization. Circ Res 5:5.
33. Sartiani L, E Bettiol, F Stillitano, A Mugelli, E Cerbai and ME Jaconi. (2007). Developmental changes in cardiomyocytes differentiated from human embryonic stem cells: a molecular and electrophysiological approach. Stem Cells 25:1136-1144.
34. Lu Z, K Kamiya, T Opthof, K Yasui and I Kodama. (2001). Density and kinetics of I(Kr) and I(Ks) in guinea pig and rabbit ventricular myocytes explain different efficacy of I(Ks) blockade at high heart rate in guinea pig and rabbit: implications for arrhythmogenesis in humans. Circulation 104:951-956.
35. Akar FG, GX Yan, C Antzelevitch and DS Rosenbaum. (2002). Unique topographical distribution of M cells underlies reentrant mechanism of torsade de pointes in the long-QT syndrome. Circulation 105:1247-1253.
36. Brouillette J, RB Clark, WR Giles and C Fiset. (2004). Functional properties of K+ currents in adult mouse ventricular myocytes. J Physiol 559:777-798.
37. Yang T, D Snyders and DM Roden. (2001). Drug block of I(kr): model systems and relevance to human arrhythmias. J Cardiovasc Pharmacol 38:737-744.
38. Snir M, I Kehat, A Gepstein, R Coleman, J Itskovitz-Eldor, E Livne and L Gepstein. (2003). Assessment of the ultrastructural and proliferative properties of human embryonic stem cell-derived cardiomyocytes. Am J Physiol Heart Circ Physiol 285:H2355-2363.
39. Huber I, I Itzhaki, O Caspi, G Arbel, M Tzukerman, A Gepstein, M Habib, L Yankelson, I Kehat and L Gepstein. (2007). Identification and selection of cardiomyocytes during human embryonic stem cell differentiation. FASEB J 21:2551-2563.
40. Rohr S, JP Kucera and AG Kleber. (1998). Slow conduction in cardiac tissue, I: effects of a reduction of excitability versus a reduction of electrical coupling on microconduction. Circ Res 83:781-794.
41. Rohr S, AG Kleber and JP Kucera. (1999). Optical recording of impulse propagation in designer cultures. Cardiac tissue architectures inducing ultra-slow conduction. Trends Cardiovasc Med 9:173-179.
42. Abildskov JA and RL Lux. (2000). Simulated torsade de pointes - the role of conduction defects and mechanism of QRS rotation. J Electrocardiol 33:55-64.
43. Shen XT and C Antzelevitch. (1986). Mechanisms underlying the antiarrhythmic and arrhythmogenic actions of quinidine in a Purkinje fiber-ischemic gap preparation of reflected reentry. Circulation 73:1342-1353.